初级预防项目中新型生物标志物测量的 早期健康技术评估方法

史蒂 夫·, 雪琳 ·露, 法汀 ·赫, 艾比 ·戴
Cambridge Sci-Med Laboratory

摘要

已有越来越多为慢性病或后续并发症风险进行分层，并具有高期望的生物标志物的发现。然而，关于在实
际临床环境中应用这些生物标志物的潜在成本效益的研究却不多。如果投资者和分析师在其开发的早期阶段先对新
生物标志物技术相关的潜在成本和影响进行指示性估计的话，他们就有机会改进并优化风险对策。为了帮助获得此
类估计，本文提出了一项对新型生物标志物技术进行早期健康技术评估的简单方法。考虑的设置是一级预防计划，
其中进行初步筛查以选择有资格进行后续干预的高风险个体，例如预防2型糖尿病。该方法基于量化所有因从基于
传统风险因素的筛查变体转变为基于传统风险因素和新型生物标志物的筛查变体而被重新分类的个人的健康结果和
下游医疗保健消费。由于这些个体形成了明确定义的亚群，疾病进展建模和敏感性分析的组合可用于对筛查成本的
最大增加进行初步评估，而使用新的生物标志物技术可能仍然具有成本效益。

关键词

生物标志物；成本效益分析；早期卫生技术评估；一级预防

参考

[1]Prieto, L. & Sacristan, J. A. (2003). Problems and

solutions in calculating quality-adjusted life years (QALYs).

Health Qual. Life Out.1 (1), 80.

[2]Horsman, J., Furlong, W., Feeny, D. & Torrance,

G. (2003). The Health Utilities Index (HUI(R)): Concepts,

measurement properties and applications. Health Qual. Life

Out.1 (1), 54.

[3]Sangar, V. K., Ragavan, N., Matanhelia, S. S., Watson,

M. W. & Blades, R. A. (2005). The economic consequences of

prostate and bladder cancer in the UK. BJU Int.95(1), 59–63.

[4]Cosh E, Girling A, Lilford R, McAteer H, Young T.

Investing in new medical technologies: a decision framework.

Journal of Commercial Biotechnology 2007; 13(4):263–271.

DOI: 10.1057/palgrave.jcb.3050062.

[5]Salomaa V, Havulinna A, Saarela O, Zeller T,

Jousilahti P, Jula A, Muenzel T, Aromaa A, Evans A,

Kuulasmaa K, Blankenberg S. Thirty-one novel biomarkers as

predictors for clinically incident diabetes. PLoS ONE 2010;

5(4):e10100. DOI: 10.1371/journal.pone.0010100.

[6]Pencina M, D’Agostino R Sr, Steyerberg E.

Extensions of net reclassification improvement calculations to

measure usefulness of new biomarkers. Statistics in Medicine

2011; 30(1):11–21. DOI: 10.1002/sim.4085.

[7]Drummond M, Sculpher M, Torrance G, O’brien B,

Stoddart G. Methods for the Economic Evaluation of Health

Care Programmes. Oxford University Press: New York, 2005.

[8]Weinstein MC, Fineberg HV. Clinical Decision

Analysis. Philadelphia: W. B. Saunders; 1980.

[9]Guzzo TJ, Vira M, Wang Y, et al. Preoperative

parameters, including percent positive biopsy, in predicting

seminal vesicle involvement in patients with prostate cancer. J

Urol. 2006;175: 518–21.

[10]Parmigiani G. Modeling in Medical Decision Making.

New York: John Wiley; 2002.

[11]Claxton K, Briggs A, Buxton M, Culyer A, McCabe

C, Walker S, Sculpher M. Value based pricing for NHS drugs:

an opportunity not to be missed? British Medical Journal 2008;

336(7638):251–254. DOI: 10.1136/bmj.39434.500185.25.

[12]Office for National Statistics (2005). Registrations

of cancer diagnosed in 2002, England, cancer statistics

registrations. Available from URL:http://www.statistics.gov.uk/

downloads/theme_health/MB1_33/MB1_33.pdf.